+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years - 69Years
All Genders
ID06918002

Phase 3 Study Comparing Elranatamab and Lenalidomide Versus Standard Chemotherapy and Transplant in Newly Diagnosed Multiple Myeloma Patients Eligible for Stem Cell Transplantation

Led by Intergroupe Francophone du Myelome · Updated on 2026-09-30

824

Participants Needed

69

Research Sites

N/A

Total Duration

AI-Summary

What this Trial Is About

Researchers are conducting a multicenter, phase 3, open-label study to evaluate treatments for patients with newly diagnosed Multiple Myeloma who are eligible for autologous stem cell transplantation ASCT. The study compares the effects of an experimental combination of elranatamab and lenalidomide against the current standard of care, including chemotherapy, ASCT, and maintenance therapies. The purpose is to assess if these new treatment approaches improve outcomes such as minimal residual disease MRD negativity and progression-free survival. Participants will first undergo induction therapy with four cycles of D-VRd daratumumab, bortezomib, lenalidomide, dexamethasone. Then, they will be randomly assigned to one of two consolidation therapies either standard treatment with high-dose chemotherapy and ASCT followed by D-VRd consolidation, or an experimental consolidation with elranatamab and lenalidomide. After consolidation, patients are re-randomized into maintenance therapy groups receiving either daratumumab plus lenalidomide or elranatamab monotherapy for approximately two years, with treatment adjustments based on MRD status. Throughout the study, participants will have scheduled visits for treatment administration, monitoring, and various assessments including blood tests, imaging, and quality of life questionnaires. Researchers will measure key outcomes such as MRD negativity rates, progression-free survival, overall survival, safety, and tolerability over several years. The study also tracks health-related quality of life and adverse events during induction, consolidation, and maintenance phases, with follow-up extending up to 11 years.

CONDITIONS

Brief Title

Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients

Research Team

J

Juliette SEON, PharmD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here